Abstract
Recent clinical studies have demonstrated the capacity of immunosuppressive therapy to delay progression of inflammatory insulitis in type 1 diabetes (T1D). The procedure includes depletion of pathogenic cells by immunosuppressive therapy and support of recovery by reinfusion of autologous hematopoietic progenitors. The short-term outcome of these clinical transplants is similar to the predictions drawn from NOD mice: debulking of diabetogenic cells is ineffectively achieved by immunosuppressive therapy, and resetting of immune homeostasis does not restrain autoimmunity. Murine models indicate that allogeneic transplants are potentially curative, through restored mechanisms of negative regulation that are effective in continuous and indefinite suppression of autoimmunity.
Keywords: Activation induced cell death, autoimmunity, Fas cross-linking, inflammation, regulatory T cells.
Current Stem Cell Research & Therapy
Title:Hematopoietic Transplants for Disease Suppression and Cure in Type 1 Diabetes
Volume: 8 Issue: 4
Author(s): Nadir Askenasy
Affiliation:
Keywords: Activation induced cell death, autoimmunity, Fas cross-linking, inflammation, regulatory T cells.
Abstract: Recent clinical studies have demonstrated the capacity of immunosuppressive therapy to delay progression of inflammatory insulitis in type 1 diabetes (T1D). The procedure includes depletion of pathogenic cells by immunosuppressive therapy and support of recovery by reinfusion of autologous hematopoietic progenitors. The short-term outcome of these clinical transplants is similar to the predictions drawn from NOD mice: debulking of diabetogenic cells is ineffectively achieved by immunosuppressive therapy, and resetting of immune homeostasis does not restrain autoimmunity. Murine models indicate that allogeneic transplants are potentially curative, through restored mechanisms of negative regulation that are effective in continuous and indefinite suppression of autoimmunity.
Export Options
About this article
Cite this article as:
Askenasy Nadir, Hematopoietic Transplants for Disease Suppression and Cure in Type 1 Diabetes, Current Stem Cell Research & Therapy 2013; 8 (4) . https://dx.doi.org/10.2174/1574888X113089990001
DOI https://dx.doi.org/10.2174/1574888X113089990001 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Balaglitazone: A Second Generation Peroxisome Proliferator-Activated Receptor (PPAR) Gamma (γ) Agonist
Mini-Reviews in Medicinal Chemistry Translating the Potential of Stem Cells for Diabetes Mellitus: Challenges and Opportunities
Current Stem Cell Research & Therapy H2O2 Signalling Pathway: A Possible Bridge between Insulin Receptor and Mitochondria
Current Neuropharmacology Opportunities for Nano-Formulations in Type 2 Diabetes Mellitus Treatments
Current Pharmaceutical Biotechnology Aldose Reductase Enzyme and its Implication to Major Health Problems of the 21st Century
Current Medicinal Chemistry Ultra-Fast Acting Insulin Analogues
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Risks Associated with SGLT2 Inhibitors: An Overview
Current Drug Safety Side Effects of Clozapine and Some Other Psychoactive Drugs
Current Drug Safety Water Soluble Vitamins and their Role in Diabetes and its Complications
Current Diabetes Reviews Clinical and Forensic Signs Related to Opioids Abuse
Current Drug Abuse Reviews Physical Activity, Insulin Action, and Diabetes Prevention and Control
Current Diabetes Reviews Brittle Type 1 Diabetes Mellitus
Current Medicinal Chemistry Half-Life of Sulfonylureas in HNF1A and HNF4A Human MODY Patients is not Prolonged as Suggested by the Mouse Hnf1a<sup>-/-</sup> Model
Current Pharmaceutical Design The TRIGR Trial: Testing the Potential Link between Weaning Diet and Type 1 Diabetes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Transporters at CNS Barrier Sites: Obstacles or Opportunities for Drug Delivery?
Current Pharmaceutical Design Fluid and Electrolyte Disorders in the Newborn: Sodium and Potassium
Current Pediatric Reviews Novel Methods of Genetic Modification of Human Pluripotent Stem Cells
Recent Patents on Regenerative Medicine The Role of Insulin Receptor Isoforms and Hybrid Insulin/IGF-I Receptors in Human Cancer
Current Pharmaceutical Design Euglycemic Diabetic Ketoacidosis: A Review
Current Diabetes Reviews Disease-Induced Neuroinflammation and Depression
CNS & Neurological Disorders - Drug Targets